Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.

Abstract

Modest up-regulation of either HER-ligands or receptors has been implicated in acquired endocrine resistance. AZD8931, a dual tyrosine kinase inhibitor (TKI) of epithelial growth factor receptor (EGFR)/HER2, has been shown to more effectively block ligand-dependent HER signaling than the HER TKIs lapatinib or gefitinib. We therefore examined the effect of AZD8931 in ER-positive/HER2-negative breast cancer cells with acquired resistance to tamoxifen, where there is ligand up-regulation associated with HER pathway activation. RNA-seq ligand profiling and levels of HER receptors and signaling by western blotting were conducted in ER+ MCF7 and T47D parental cells and their Tam-resistant derivatives (TamRes). In vitro cell growth and apoptosis and HER ligand-stimulated signaling were measured in response to endocrine and HER TKIs. For studies in vivo, transplantable MCF7/TamRes xenografts were treated with tamoxifen or fulvestrant, either alone or in combination with AZD8931. AZD8931 only minimally enhanced endocrine sensitivity in MCF7 parental cells, but showed a greater effect in the T47D parental model. AZD8931 combined with either tamoxifen or fulvestrant inhibited cell growth more than lapatinib in T47D TamRes cells, and was also significantly, though modestly, more potent in MCF7 TamRes cells. In both TamRes models, AZD8931 significantly inhibited cell proliferation and induced apoptosis. Under ligand-stimulated conditions, AZD8931 more potently inhibited HER signaling than lapatinib or gefitinib. AZD8931 also significantly delayed the growth of MCF7 TamRes xenografts in the presence of tamoxifen or fulvestrant. The strongest inhibition was achieved with a fulvestrant and AZD8931 combination, though no tumor regression was observed. This study provides evidence that AZD8931 has greater inhibitory efficacy in tamoxifen-resistant settings than in an endocrine therapy naïve setting. The absence of tumor regression, however, suggests that additional escape pathways contribute to resistant growth and will need to be targeted to fully circumvent tamoxifen resistance.

• Authors: Gladys Morrison, Xiaoyong Fu, Martin Shea, Sarmistha Nanda, Mario Giuliano, Tao Wang, Teresa Klinowska, C Kent Osborne, Mothaffar F Rimawi, Rachel Schiff
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 144 Issue 2 Pg. 263-72 (Apr 2014) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 24554387 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• AZD 8931
• Quinazolines
• Receptors, Estrogen
• Tamoxifen
• Lapatinib
• Fulvestrant
• Estradiol
• EGFR protein, human
• ErbB Receptors
• Receptor, ErbB-2
• Gefitinib

Topics

• Animals
• Apoptosis (drug effects)
• Breast Neoplasms (drug therapy, genetics, pathology)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Drug Resistance, Neoplasm
• ErbB Receptors (antagonists & inhibitors, genetics)
• Estradiol (analogs & derivatives, pharmacology)
• Female
• Fulvestrant
• Gefitinib
• Humans
• Lapatinib
• MCF-7 Cells
• Mice
• Mice, Nude
• Quinazolines (pharmacology)
• Random Allocation
• Receptor, ErbB-2 (antagonists & inhibitors, genetics)
• Receptors, Estrogen (genetics)
• Signal Transduction (drug effects)
• Tamoxifen (pharmacology)
• Up-Regulation (drug effects)
• Xenograft Model Antitumor Assays